SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Ling Zhang, Qian Lu, Zhiqing Yang, Xiaojun Wang, Lei Cai, Xiangde Liu, Rui Liao, Xing Yang, Yinzhi Chen, Zhanyu Yang, Association of rs12979860 and rs8099917 polymorphisms near IL28B with SVR in hepatic allograft recipients with HCV recurrence undergoing PEG-IFN/RBV therapy: A meta-analysis, Human Immunology, 2014, 75, 12, 1268

    CrossRef

  2. 2
    I. Campos-Varela, J. I. Esteban, M. Bes, M. Caralt, H. Allende, F. Rodríguez-Frías, M. T. Salcedo, S. Sauleda, R. Charco, J. Guardia, R. Esteban, L. Castells, Early predictors of antiviral treatment response in liver transplant recipients with recurrent hepatitis C genotype 1, Journal of Viral Hepatitis, 2014, 21, 10
  3. 3
    Sabela Lens, Zoe Mariño, Xavier Forns, Efficacy of new direct acting antivirals in transplant recipients and patients with advanced disease, Digestive and Liver Disease, 2014, 46, S197

    CrossRef

  4. 4
    V. Aguilera, Hepatitis C Virus Recurrence After Liver Transplantation: How to Treat and When, Transplantation Proceedings, 2014, 46, 9, 3100

    CrossRef

  5. 5
    Carlos Fernández-Carrillo, Mairene Coto-Llerena, Patricia González, Gonzalo Crespo, Laura Mensa, Noelia Caro-Pérez, Martina Gambato, Miquel Navasa, Xavier Forns, Sofía Pérez-del-Pulgar, IFNL4 polymorphism predicts response to hepatitis C treatment after liver transplantation, Journal of Clinical Virology, 2014, 61, 2, 282

    CrossRef

  6. 6
    Tzu-Hao Lee, Hans L. Tillmann, Keyur Patel, Individualized Therapy for Hepatitis C Infection: Focus on the Interleukin-28B Polymorphism in Directing Therapy, Molecular Diagnosis & Therapy, 2014, 18, 1, 25

    CrossRef

  7. 7
    Ar Kar Aung, David W Haas, Todd Hulgan, Elizabeth J Phillips, Pharmacogenomics of antimicrobial agents, Pharmacogenomics, 2014, 15, 15, 1903

    CrossRef

  8. 8
    Marina Kawaguchi-Suzuki, Reginald F. Frye, The Role of Pharmacogenetics in the Treatment of Chronic Hepatitis C Infection, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2014, 34, 2
  9. 9
    Martina Gambato, Sabela Lens, Miquel Navasa, Xavier Forns, Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation, Journal of Hepatology, 2014, 61, 1, S120

    CrossRef

  10. 10
    Tomokazu Kawaoka, Shoichi Takahashi, Yumiko Tatsukawa, Akira Hiramatsu, Nobuhiko Hiraga, Daiki Miki, Masataka Tsuge, Michio Imamura, Yoshiiku Kawakami, Hiroshi Aikata, Hidenori Ochi, Kouhei Ishiyama, Kentaro Ide, Hirotaka Tashiro, Hideki Ohdan, Kazuaki Chayama, Two patients treated with pegylated interferon/ribavirin/telaprevir triple therapy for recurrent hepatitis C after living donor liver transplantation, Hepatology Research, 2014, 44, 12
  11. 11
    A.J. Thompson, P. Clark, A. Aghemo, Handbook of Pharmacogenomics and Stratified Medicine, 2014,

    CrossRef

  12. 12
    Roberto J. Firpi, Huijia Dong, Virginia C. Clark, Consuelo Soldevila-Pico, Giuseppe Morelli, Roniel Cabrera, Oxana Norkina, Jonathan J. Shuster, David R. Nelson, Chen Liu, CC genotype donors for the interleukin-28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant, Liver International, 2013, 33, 1
  13. 13
    Gonzalo Crespo, José A. Carrión, Mairene Coto-Llerena, Zoe Mariño, Sabela Lens, Sofía Pérez-del-Pulgar, Montserrat García-Retortillo, Rosa Miquel, Jaime Bosch, Miquel Navasa, Xavier Forns, Combinations of simple baseline variables accurately predict sustained virological response in patients with recurrent hepatitis C after liver transplantation, Journal of Gastroenterology, 2013, 48, 6, 762

    CrossRef

  14. 14
    Scott W. Biggins, James Trotter, Jane Gralla, James R. Burton, Kiran M. Bambha, Jennifer Dodge, Megan Brocato, Linling Cheng, Matt McQueen, Lisa Forman, Michael Chang, Igal Kam, Gregory Everson, Richard A. Spritz, Goran Klintmalm, Hugo R. Rosen, Differential effects of donor and recipient IL28B and DDX58 SNPs on severity of HCV after liver transplantation, Journal of Hepatology, 2013, 58, 5, 969

    CrossRef

  15. 15
    Marina Berenguer, Bruno Roche, Victoria Aguilera, Jean-Charles Duclos-Vallée, Laia Navarro, Angel Rubín, Jose-Antonio Pons, Manuel de la Mata, Martín Prieto, Didier Samuel, Efficacy of the retreatment of hepatitis C virus infections after liver transplantation: Role of an aggressive approach, Liver Transplantation, 2013, 19, 1
  16. 16
    G. Grammatikos, C. Sarrazin, IL28B und antivirale Therapie der Virushepatitis: Was bleibt?, Der Gastroenterologe, 2013, 8, 4, 322

    CrossRef

  17. 17
    Markus H. Heim, Innate immunity and HCV, Journal of Hepatology, 2013, 58, 3, 564

    CrossRef

  18. 18
    Davide Bitetto, Tullia De Feo, Martina Mantovani, Edmondo Falleti, Carlo Fabris, Luca Saverio Belli, Stefano Fagiuoli, Patrizia Burra, Giuseppe Piccolo, Maria Francesca Donato, Pierluigi Toniutto, Interaction between calcineurin inhibitors and IL-28B rs12979860 C>T polymorphism and response to treatment for post-transplant recurrent hepatitis C, Digestive and Liver Disease, 2013, 45, 11, 927

    CrossRef

  19. 19
    Andres Duarte-Rojo, Matthew G. Deneke, Michael R. Charlton, Interleukin-28B polymorphism in hepatitis C and liver transplantation, Liver Transplantation, 2013, 19, 1
  20. 20
    Maria-Carlota Londoño, Gonzalo Crespo, Xavier Forns, Pretransplant and posttransplant treatment of hepatitis C virus infection with protease inhibitors, Current Opinion in Organ Transplantation, 2013, 18, 3, 271

    CrossRef

  21. 21
    Marina Berenguer, Detlef Schuppan, Progression of liver fibrosis in post-transplant hepatitis C: Mechanisms, assessment and treatment, Journal of Hepatology, 2013, 58, 5, 1028

    CrossRef

  22. 22
    S. Friman, Recurrence of Disease After Liver Transplantation, Transplantation Proceedings, 2013, 45, 3, 1178

    CrossRef

  23. 23
    Christian M. Lange, The importance of IL28B genotype in hepatitis C virus-associated liver transplantation, Liver International, 2013, 33, 2
  24. 24
    J. Levitsky, K. Doucette, Viral Hepatitis in Solid Organ Transplantation, American Journal of Transplantation, 2013, 13, s4
  25. 25
    Marina Berenguer, Victoria Aguilera, Angel Rubín, Cecilia Ortíz, Martina Jimenez, Martín Prieto, Comparison of two non-contemporaneous HCV-liver transplant cohorts: Strategies to improve the efficacy of antiviral therapy, Journal of Hepatology, 2012, 56, 6, 1310

    CrossRef

  26. 26
    Mairene Coto-Llerena, Gonzalo Crespo, Patricia González, George Koutsoudakis, Rosa Miquel, Miquel Navasa, Xavier Forns, Sofía Pérez-del-Pulgar, Determination of IL28B polymorphisms in liver biopsies obtained after liver transplantation, Journal of Hepatology, 2012, 56, 2, 355

    CrossRef

  27. 27
    J. A. Holmes, P. V. Desmond, A. J. Thompson, Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection?, Journal of Viral Hepatitis, 2012, 19, 10
  28. 28
    Ivo W. Graziadei, Heinz M. Zoller, Anna Schloegl, Karin Nachbaur, Karl-Peter Pfeiffer, Walter Mark, Gregor Mikuz, Johann Pratschke, Raimund Margreiter, Wolfgang Vogel, Early viral load and recipient interleukin-28B rs12979860 genotype are predictors of the progression of hepatitis C after liver transplantation, Liver Transplantation, 2012, 18, 6
  29. 29
    C. Nelson Hayes, Michio Imamura, Hiroshi Aikata, Kazuaki Chayama, Genetics of IL28B and HCV—response to infection and treatment, Nature Reviews Gastroenterology & Hepatology, 2012, 9, 7, 406

    CrossRef

  30. You have free access to this content30
    Luke W. Meredith, Garrick K. Wilson, Nicola F. Fletcher, Jane A. McKeating, Hepatitis C virus entry: beyond receptors, Reviews in Medical Virology, 2012, 22, 3
  31. 31
    Varun Saxena, Norah Terrault, Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies, Current Opinion in Organ Transplantation, 2012, 17, 3, 216

    CrossRef

  32. 32
    Bruno Roche, Didier Samuel, Hepatitis C virus treatment pre- and post-liver transplantation, Liver International, 2012, 32,
  33. 33
    Christoph T. Berger, Arthur Y. Kim, IL28B Polymorphisms as a Pretreatment Predictor of Response to HCV Treatment, Infectious Disease Clinics of North America, 2012, 26, 4, 863

    CrossRef

  34. 34
    Elisa Cisneros, Isolina Baños, María Jesús Citores, Ana Duca, Clara Salas, Ana Noblejas, María Cañizares, Isabel Millán, Valentín Cuervas-Mons, Carlos Vilches, Increased Risk of Severe Hepatitis C Virus Recurrence After Liver Transplantation in Patients With a T Allele of IL28B rs12979860, Transplantation Journal, 2012, 94, 3, 275

    CrossRef

  35. 35
    Tomokazu Kawaoka, Shoichi Takahashi, Shintaro Takaki, Akira Hiramatsu, Koji Waki, Nobuhiko Hiraga, Daiki Miki, Masataka Tsuge, Michio Imamura, Yoshiiku Kawakami, Hiroshi Aikata, Hidenori Ochi, Takashi Onoe, Hirotaka Tashiro, Hideki Ohdan, Kazuaki Chayama, Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation, Journal of Gastroenterology and Hepatology, 2012, 27, 9
  36. 36
    Norah Terrault, Liver transplantation in the setting of chronic HCV, Best Practice & Research Clinical Gastroenterology, 2012, 26, 4, 531

    CrossRef

  37. 37
    Nicholas A. Shackel, Looking into Pandora's box , Liver Transplantation, 2012, 18, 3
  38. 38
    Y. Chen, H.-X. Xu, L.-J. Wang, X.-X. Liu, R. I. Mahato, Y.-R. Zhao, Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin, Alimentary Pharmacology & Therapeutics, 2012, 36, 2
  39. 39
    V. Soriano, E. Poveda, E. Vispo, P. Labarga, N. Rallon, P. Barreiro, Pharmacogenetics of hepatitis C, Journal of Antimicrobial Chemotherapy, 2012, 67, 3, 523

    CrossRef

  40. 40
    Maria Francesca Donato, Enrico Galmozzi, Cristina Rigamonti, Alessio Aghemo, Post-liver transplantation graft biopsies should not be used to assess the IL28B donor genotype in HCV recipients, Journal of Hepatology, 2012, 56, 6, 1422

    CrossRef

  41. 41
    T. Hibi, J. Sageshima, E. Molina, G. Ciancio, S. Nishida, L. Chen, L. Arosemena, A. Mattiazzi, G. Guerra, W. Kupin, A. Tekin, G. Selvaggi, D. Levi, P. Ruiz, A. S. Livingstone, D. Roth, P. Martin, A. Tzakis, G. W. Burke, Predisposing Factors of Diminished Survival in Simultaneous Liver/Kidney Transplantation, American Journal of Transplantation, 2012, 12, 11
  42. 42
    Varun Saxena, Jennifer C. Lai, Jacqueline G. O'Leary, Elizabeth C. Verna, Robert S. Brown, R. Todd Stravitz, James F. Trotter, Kartik Krishnan, Norah A. Terrault, Recipient-Donor race mismatch for African American liver transplant patients with chronic hepatitis C, Liver Transplantation, 2012, 18, 5
  43. 43
    Marina Berenguer, Ramón Charco, Juan Manuel Pascasio, Jose Ignacio Herrero, Spanish society of liver transplantation (SETH) consensus recommendations on hepatitis C virus and liver transplantation, Liver International, 2012, 32, 5
  44. 44
    Andres Duarte-Rojo, Bart J. Veldt, David D. Goldstein, Hans L. Tillman, Kymberly D. Watt, Julie K. Heimbach, John G. McHutchison, John J. Poterucha, Florencia Vargas-Vorackova, Michael R. Charlton, The Course of Posttransplant Hepatitis C Infection, Transplantation Journal, 2012, 94, 2, 197

    CrossRef

  45. 45
    Gonzalo Crespo, Zoe Mariño, Miquel Navasa, Xavier Forns, Viral Hepatitis in Liver Transplantation, Gastroenterology, 2012, 142, 6, 1373

    CrossRef

  46. 46
    Eleonora De Martin, Kryssia I Rodriguez-Castro, Alessandro Vitale, Giacomo Zanus, Marco Senzolo, Francesco Paolo Russo, Patrizia Burra, Antiviral treatment for HCV recurrence after liver transplantation: when, how much and for how long?, Future Virology, 2011, 6, 10, 1179

    CrossRef

  47. 47
    F. Xavier López-Labrador, Marina Berenguer, Genomic medicine reaches HCV-related liver transplantation: Hopes and clinical and public health implications, Journal of Hepatology, 2011, 55, 2, 270

    CrossRef

  48. 48
    A. Rubín, V. Aguilera, M. Berenguer, Liver transplantation and hepatitis C, Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 12, 805

    CrossRef

  49. 49
    J. A. Wertheim, H. Petrowsky, S. Saab, J. W. Kupiec-Weglinski, R. W. Busuttil, Major Challenges Limiting Liver Transplantation in the United States, American Journal of Transplantation, 2011, 11, 9
  50. 50
    Reddy K Rajender, Chalermrat Bunchorntavakul, Managing hepatitis C: Before and after liver transplantation, Indian Journal of Transplantation, 2011, 5, 2, 72

    CrossRef

  51. 51
    Marina Berenguer, Treatment of hepatitis C in the post-transplant setting, Digestive and Liver Disease Supplements, 2011, 5, 1, 26

    CrossRef

  52. 52
    Kiran Bambha, Norah A. Terrault, Long-Term Management of Recurrent Primary Liver Disease,
  53. 53
    Samir Parekh, James R. Spivey, Recurrent Disease after Liver Transplantation,